Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

88
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
88
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Cancer Survival Analysis01:21

Cancer Survival Analysis

334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
Cancer Vaccines01:30

Cancer Vaccines

347
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
347

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Symptom prevalence and impact on lung cancer risk in the SUMMIT study.

Chest·2026
Same author

Immunotherapy-related interstitial lung disease: a call to improve risk stratification and diagnostic consistency.

ERJ open research·2026
Same author

Implementing Digital Respiratory Technologies for People With Respiratory Conditions: Scoping Review.

Journal of medical Internet research·2026
Same author

Brief Report: Impact of PLCOm2012 Ethnicity Model Variations on Eligibility for the Alberta Lung Cancer Screening Program.

JTO clinical and research reports·2026
Same author

Expanded detection of early fibrotic phenotypes using lobar traction bronchiolectasis in lung cancer screening.

American journal of respiratory and critical care medicine·2026
Same author

Find your career: the ERS "My Career Path" series.

Breathe (Sheffield, England)·2026
Same journal

A hypermetabolic pulmonary lesion in a patient with breast cancer.

Breathe (Sheffield, England)·2026
Same journal

Rigid bronchoscopy is the gold standard management of inhaled foreign bodies in children: myth or maxim?

Breathe (Sheffield, England)·2026
Same journal

The price of immune awakening: bridging knowledge gaps in checkpoint inhibitor-related pneumonitis in lung cancer.

Breathe (Sheffield, England)·2026
Same journal

Where are we with biomarkers in paediatric asthma in 2026?

Breathe (Sheffield, England)·2026
Same journal

Recurrent invasive fungal infection with locally advanced thymoma: diagnostic challenges in complex mediastinal disease.

Breathe (Sheffield, England)·2026
Same journal

Elevated <i>D</i> <sub>LCO</sub> and pulmonary function evolution during treatment in a patient with hyperleukocytosis and leukostasis.

Breathe (Sheffield, England)·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.6K

Lung cancer screening: where do we stand?

Georgia Hardavella1, Armin Frille2, Katherina Bernadette Sreter3

  • 14th-9th Department of Respiratory Medicine, 'Sotiria' Athens' Chest Diseases Hospital, Greece.

Breathe (Sheffield, England)
|August 28, 2024
PubMed
Summary
This summary is machine-generated.

Lung cancer screening (LCS) programs are expanding globally, with low-dose CT scans and smoking cessation proving effective. Advanced tools like AI and biomarkers show promise but need further validation.

More Related Videos

Use of Electromagnetic Navigational Transthoracic Needle Aspiration E-TTNA for Sampling of Lung Nodules
06:03

Use of Electromagnetic Navigational Transthoracic Needle Aspiration E-TTNA for Sampling of Lung Nodules

Published on: May 23, 2015

22.3K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

Related Experiment Videos

Last Updated: Jun 15, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.6K
Use of Electromagnetic Navigational Transthoracic Needle Aspiration E-TTNA for Sampling of Lung Nodules
06:03

Use of Electromagnetic Navigational Transthoracic Needle Aspiration E-TTNA for Sampling of Lung Nodules

Published on: May 23, 2015

22.3K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

Area of Science:

  • Pulmonology
  • Oncology
  • Radiology

Background:

  • Lung cancer screening (LCS) programs are increasingly implemented worldwide, exhibiting variations in delivery, eligibility, and resource management.
  • Currently, only a limited number of national LCS programs are fully established, with more expected in the future.

Purpose of the Study:

  • To review the current landscape of lung cancer screening programs.
  • To highlight effective components of LCS programs, such as low-dose computed tomography (LDCT) and smoking cessation.
  • To discuss emerging technologies for enhancing LCS.

Main Methods:

  • Review of existing literature and evidence on lung cancer screening programs.
  • Analysis of current practices and outcomes associated with LCS.
  • Exploration of novel tools and technologies in LCS.

Main Results:

  • Low-dose chest computed tomography (LDCT) combined with smoking cessation significantly improves patient outcomes in LCS.
  • Emerging technologies such as refined risk prediction models, biomarkers, artificial intelligence (AI), and radiomics show potential for improving LCS.
  • These advanced tools require additional research and clinical validation before widespread adoption.

Conclusions:

  • Lung cancer screening programs are evolving, with LDCT and smoking cessation as core components.
  • Innovative technologies like AI and radiomics hold promise for the future of LCS but necessitate further validation.
  • The integration of new tools into routine LCS practice should be approached cautiously, prioritizing clinical evidence.